Gilead Sciences reported quarterly EPS of $2.03, beating the Zacks consensus estimate of $1.89 by $0.14, and up from $1.81 a year ago. The result indicates better-than-expected operating performance and modest year-over-year earnings growth. The headline is supportive for the stock, though the article provides no guidance or revenue details.
Gilead Sciences reported quarterly EPS of $2.03, beating the Zacks consensus estimate of $1.89 by $0.14, and up from $1.81 a year ago. The result indicates better-than-expected operating performance and modest year-over-year earnings growth. The headline is supportive for the stock, though the article provides no guidance or revenue details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.34
Ticker Sentiment
